Strategic partnerships Opportunity to deepen collaboration with large diagnostics players and academic collaborators, leveraging Fujirebio’s history of partnerships to co-develop and co-commercialize biomarker-driven IVD solutions. Focus on expanding joint development programs and licensing deals, particularly around new biomarkers and automated testing platforms.

Alzheimer's expansion Recent activity around Alzheimer’s biomarkers and the LOI with Alzinova signals a growth avenue for blood-based Alzheimer’s diagnostics. Target clinicians and labs seeking scalable NfL and Aβ42-based assays, and explore opportunities with neurology centers and research consortia.

Neuro diagnostics toolbox Launch of Neuro Expert Toolbox (NExT) presents a product bundle for advanced neurology and neurodegenerative testing. Position as an integrated solution for comprehensive biomarker panels, aiming at reference labs and hospital systems needing turnkey neuro diagnostics workflows.

Strategic acquisitions Acquisition of Plasma Services Group and broader material supply strength open upsell paths for raw materials, bioreagents, and traceable materials used in IVD production. Cross-sell supply chain resilience offerings to augment customers’ manufacturing reliability.

Global reach with local support Diversified geographic footprint and consolidated subsidiary structure enable regional account strategies. Emphasize localized regulatory support, CE marking capabilities, and rapid deployment for labs across the US, Europe, and Asia to shorten time-to-market for new assays.